RxDoctor Payments Data

Arthur Patton, MD

Internal Medicine · Gardendale, ALNPI 1003855149

Payments from drug & device makers

$1,053in general payments, 2019–2025

Across 60 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$395
  • Exact Sciences$143
  • Lilly USA, LLC$136
  • Pfizer$73
  • GSK$69
  • AbbVie$55
  • plus $183 from 10 others

What the payments were for

  • Food & beverage$1,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,053 in reported general payments places this provider in the 60th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$70,816
Medicare patients
149
Services billed
1,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$145,214
EliquisApixaban126$109,708
RybelsusSemaglutide56$60,291
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$51,358
MounjaroTirzepatide33$49,734
JardianceEmpagliflozin63$45,637
FarxigaDapagliflozin Propanediol35$26,445
TradjentaLinagliptin44$25,431
TrulicityDulaglutide11$20,086
JanuviaSitagliptin Phosphate23$17,960
XareltoRivaroxaban18$17,935
Breo ElliptaFluticasone/Vilanterol24$13,094
LinzessLinaclotide16$11,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog53$9,705
Tresiba Flextouch U-100Insulin Degludec13$8,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$395$205,504171 claims
PfizerEliquis$73$109,708126 claims
Boehringer IngelheimJardiance, Tradjenta$47$71,069107 claims
Lilly USA, LLCMounjaro, Trulicity$136$69,82044 claims
GSKTrelegy Ellipta, Breo Ellipta$69$64,45281 claims
Johnson & JohnsonXarelto$11$17,93518 claims
AbbVieLinzess$55$11,31016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Gardendale

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →